Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: J Surg Oncol. 2017 Jun 19;116(3):320–328. doi: 10.1002/jso.24666

Figure 3.

Figure 3

Kaplan-Meier survival curve for patients with ovarian high-grade serous carcinoma treated with multimodality therapy including cytoreductive surgery (CRS)-hyperthermic intraperitoneal chemoperfusion (HIPEC) and systemic chemotherapy (n=62). The estimated median overall survival from CRS-HIPEC was 38.0 months (95% CI 21.3 to 68.9 months) for platinum-sensitive disease (“platsensitive”), and 37.2 months (95% CI 0.9 to 65.1 months) for platinum-resistant or refractory disease (“platresistrefract”).